Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Pyrimidines (including hydrogenated) (e.g., cytosine, etc.)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514023000 - Carbohydrate (i.e., saccharide radical containing) DOAI

514042000 - N-glycoside

514043000 - Nitrogen containing hetero ring

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514050000 2,4-diketone pyrimidine or derivative (e.g., uracil, etc.) 93
Entries
DocumentTitleDate
20130045944Anti-Cancer Therapies - Methods for the treatment of cancer are described. In particular, methods for treatment of cancer comprising administration of glufosfamide alone or in combination with another anticancer agent are disclosed.02-21-2013
20120184505MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS - In its many embodiments, the present invention provides a novel class of pyrimidine analogs as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discussed are suitable combinations of the cell cycle checkpoint modulator with a checkpoint kinase inhibitor to produce synergistic apoptosis in cancer cells. The invention also includes methods of treating cancers by administering the combination of the cell cycle checkpoint modulator and the checkpoint kinase inhibitor, pharmaceutical compositions comprising the cell cycle checkpoint modulator as well as combinations and pharmaceutical kits. An example cell cycle checkpoint modulator is shown below: formula (I).07-19-2012
20090197826P-Toluene Sulfonic Acid Salt of 5-Amino-3-(2'-O-Acetyl-3'-Deoxy-Beta-D-Ribofuranosyl)-3H-Thiazole[4,5-d]p- yrimidine-2-one and Methods for Preparation - The present disclosure relates to p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and to its use in treating conditions such as viral infections, tumors, and cancer.08-06-2009
20090312280COMBINATION THERAPY OF (2R,Z)-2-AMINO-2-CYCLOHEXYL-N-(5-(1-METHYL-1H-PYRAZOL-4-YL)-1-OXO-2,6-DIH- YDRO-1H-[1,2]DIAZEPINO[4,5,6-CD]INDOL-8-YL)ACETAMIDE - The present invention relates to novel combination therapies of (2R,Z)-2-amino-2-cyclohexyl-N-(5-(1-methyl-1H-pyrazol-4-yl)-1-oxo-2,6-dihydro -1H-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide (compound 1), a pharmaceutically acceptable salt thereof, or a mixture thereof, in combination with an anti-cancer agent or radiation therapy.12-17-2009
20100009929COMPOSITIONS INCLUDING TRICIRIBINE AND BORTEZOMIB AND DERIVATIVES THEREOF AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.01-14-2010
20110195924Methods of Inhibiting the Interaction Between S100P and the Receptor for Advanced Glycation End-Products - A method of inhibiting an interaction between a S100 protein and the receptor for advanced glycation end-products is provided comprising administering to a subject a therapeutically effective amount of cromolyn, C5, and/or other analogs, or salts, hydrates, or solvates thereof. In addition, provided herein are methods of treating a cancer comprising administering to a mammal a therapeutically effective amount of cromolyn, C5, and/or other analogs, or salts, hydrates, or solvates thereof.08-11-2011
20130085116COMPOSITIONS INCLUDING TRICIRIBINE AND EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR COMPOUNDS OR SALTS THEREOF AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.04-04-2013
20100075915METHODS FOR CANCER THERAPY AND STEM CELL MODULATION - The present invention relates to a method of inducing apoptosis in a tumour cell as well as modulating pluripotency and/or self-renewing characteristics of a stem/progenitor cell. The method comprises administering to the respective cell a compound of general formula (I). In general formula A is C or N. R03-25-2010
20100075916SUBSTITUTED QUINAZOLINE INHIBITORS OF GROWTH FACTOR RECEPTOR TYROSINE KINASES - The present invention relates to new substituted quinazoline inhibitors of vascular endothelial growth factor receptor tyrosine kinase, epidermal growth factor receptor tyrosine kinase, and/or REarranged during Transfection tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof.03-25-2010
20120245117METHODS OF TREATING SQUAMOUS CELL LUNG CANCER WITH 4-IODO-3-NITROBENZAMIDE IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN - In one aspect, the present invention provides a method of treating squamous cell lung cancer in an individual comprising administering to the individual having lung cancer an effective amount of 4-iodo-3-nitrobenzamide or a metabolite thereof or pharmaceutically acceptable salt thereof; gemcitabine; and carboplatin.09-27-2012
20130079297KINASE PROTEIN BINDING INHIBITORS - The invention relates to phosphorylation inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating cell proliferative disorders, especially cancer.03-28-2013
20130040909COMPOSITIONS INCLUDING TRICIRIBINE AND ONE OR MORE PLATINUM COMPOUNDS AND METHODS OF USE THEREOF - This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.02-14-2013
20120264711ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.10-18-2012
20090156547AMIDE PRODRUG OF GEMCITABINE, COMPOSITIONS AND USE THEREOF - The present invention relates to novel amide prodrugs of gemcitabine, compositions thereof and methods for using.06-18-2009
20100144664CARBOCYCLIC COMPOUNDS AND METHODS FOR TREATING EMERGING DISEASE, INCLUDING INFLUENZA AND VENEZUELA EQUINE ENCEPHALITIS VIRUS - The present invention relates to the use of carbodine and 5-F carbodine and analogs thereof for use in the treatment or prophylaxis of influenza, in particular the H5N1 strain of Avian Influenza A virus or “bird flu” strain of influenza as well as the treatment or prophylaxis of Venezuela equine encephalitis virus or VEE.06-10-2010
20120165287COMBINED TREATMENT OF CANCER BY UROKINASE INHIBITION AND A CYTOSTATIC ANTI-CANCER AGENT FOR ENHANCING THE ANTI-METASTATIC EFFECT - The present invention relates to a combined treatment of cancer using a urokinase inhibitor and a cytotoxic or a cytostatic agent.06-28-2012
20130090303Agonists of PY2Y Receptor as a Treatment for Aortic Stenosis and Cardiovascular Calcification - The present invention relates to the treatment and/or prevention of aortic valve stenosis (AVS) and valve mineralization. Particularly, the invention provides a target for intervention in the treatment or prevention of AVS through the administration of the P2Y04-11-2013
200903060083'-ETHYNYLCYTIDINE DERIVATIVE - To provide a compound which exhibits excellent anti-tumor activity and excellent oral absorption and which is a useful anti-tumor drug.12-10-2009
20130059811METHOD FOR TREATING AND PREVENTING ARTHRITIS - Compounds represented by the formula 1:03-07-2013
20110015148ANTIVIRAL NUCLEOSIDES - 4-Amino-1-((2R,3S,4S,5R)-5-azido-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one (22) and prodrugs thereof are hepatitis C (HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for making the compounds and synthetic intermediates employed in the process.01-20-2011
20110015147ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES - A compound of formula (I) wherein Ar can be one six-membered or two fused six-membered aromatic rings; R01-20-2011
20090270341PRODUCT COMPRISING A TRANSDUCTION INHIBITOR OF HETEROTRIMERIC G PROTEIN SIGNALS COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN THE TREATMENT OF CANCER - A composition for treating cancer comprising an anti-tumorally effective amount of a product comprising at least one transduction inhibitor of heterotrimeric G protein signals and at least one other anti-cancer agent selected from the group consisting of prenyltransferase inhibitors, taxol and its analogues, gemcitabine and camptothecin and its analogues, administered simultaneously, separately or spread over a period of time and a pharmaceutical carrier.10-29-2009
20090270340METHODS OF ADMINISTERING ANTITUMOR AGENT COMPRISING DEOXYCYTIDINE DERIVATIVE - Antitumor treatment regimens comprising: administering, to a patient diagnosed with cancer, an antitumor agent comprising 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone, or a salt thereof, by way of continuous intravenous infusion, in an amount of 2.0 to 4.0 mg per m10-29-2009
20090325897DESIGNER THERAPY OF PANCREATIC TUMORS - Chemotherapeutic and Radiation sensitizing agents which target tumor cells, specifically, based on the elevation of enzyme pathways, provide highly selective drug therapy. These agents are combined with modulating doses of cytidine deaminase inhibitors to increase selectivity. Furthermore, high doses of these cytidine deaminase inhibitors have the potential of counteracting the aggressive and metastatic characteristics of pancreatic tumors. For tumors with high levels of cytidine deaminase, such as pancreatic tumors, this elevation provides a therapeutic approach with prodrugs that require deamination for their activation. For tumors with high levels of uridine/cytidine kinase, a different class of pyrimidine analogs can be activated selectively in tumors for a therapeutic advantage.12-31-2009
20120115806Antitumor Combination Including Cabazitaxel and Capecitabine - The invention relates to a method of treatment of metastatic breast cancer in a patient progressing after a previous anthracycline and/or taxane treatment, said method comprising administering to said patient a combination of antitumor agents comprising cabazitaxel and capecitabine, wherein each of said antitumor agents, independently, may be in the form of a base, in the form of a pharmaceutically acceptable acid salt or in the form of a hydrate or solvate.05-10-2012
20100016254GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The present invention provides gemcitabine prodrugs, methods of making gemcitabine prodrugs, pharmaceutical compositions of gemcitabine prodrugs and methods of using gemcitabine prodrugs and pharmaceutical compositions of using gemcitabine prodrugs to treat or prevent diseases or disorders such as cancer or viral infections.01-21-2010
20100087387FIVE- AND SIX-MEMBERED CONFORMATIONALLY LOCKED 2',4'-CARBOCYCLIC RIBO-THYMIDINES FOR THE TREATMENT OF INFECTIONS AND CANCER - Compounds (1, 2, 3, 4) according to the formulae shown below: (Formula 1, 2, 3, 4). For General Formula1-4:N=1-Thyminyl,9-Adeninyl,9-Guaninyl,1-Cytosinyl, 5-methyl-1-cytosinyl, 5-trifluoromethyl-1-cytosinyl, 5-fluoro-1-cytosinyl, 5-fluoro-1-cytosinyl, 5-trifluoromethyl-1-Uracilyl or Formula (A) (12a/12b) wherein for 12a: n=1, Q=CH04-08-2010
20080293668[5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides - A method and composition for the treatment of HIV and HBV infections in humans and other host animals is disclosed that includes the administration of an effective amount of a [5-carboxamido or 5-fluoro]-2′,3′-dideoxy-2′,3′-didehydro-pyrimidine nucleoside or a [5-carboxamido or 5-fluoro]-3′-modified-pyrimidine nucleoside, or a mixture or a pharmaceutically acceptable derivative thereof, including a 5′ or N11-27-2008
20090082306DEUTERIUM-ENRICHED TELBIVUDINE - The present application describes deuterium-enriched telbivudine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-26-2009
20100197627PANCREATIC CANCER TREATMENT08-05-2010
20110281815Parental formulations of gemcitabine derivatives - The present invention relates to parenteral formulations for certain long chain saturated and monounsaturated fatty acid derivatives of 2′,2′-difluorodeoxycytidine (Gemcitabine). In particular, the present invention relates to a parenteral pharmaceutical composition and a method of the preparation thereof, in order to accommodate therapeutically effective doses of the said derivatives ameliorating compliance in treatment of cancer.11-17-2011
20110065664KINASE PROTEIN BINDING INHIBITORS - The invention relates to phosphorylation inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating cell proliferative disorders, especially cancer.03-17-2011
20110301113PYRIDINEAMINE DERIVATIVES - This invention relates to novel compounds that are pyrimidineamine derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrimidineamine derivatives that are derivatives of pazopanib. This invention also provides compositions comprising one or more compound of this invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a VEGFR (1-3) inhibitor, such as pazopanib.12-08-2011
20090298790NOVEL THERAPEUTIC USE FOR TREATING OF LEUKEMIA - The disclosure relates to methods of treating leukaemia, in particular myeloid leukaemia, comprising administering the compound N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N′-(1,1-dimethylethyl)-urea or a hydrate, a pharmaceutically acceptable salt or a solvate thereof.12-03-2009
20110301114AMPHIPHILE PRODRUGS - Amphiphilic prodrugs of general formula A-X are disclosed, wherein A is a biologically active agent or may be metabolised to a biologically active agent; and X is selected from the group consisting of R, or up to three R moieties attached to a linker, Y12-08-2011
20110275590CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS - The present invention relates to conjugates of a drug and an amino acid or an amino acid derivative or analog, pharmaceutical compositions that include the conjugates and methods of use thereof. In particular, the present invention relates to conjugates of anti-proliferative drugs and asparagine and glutamine and analogs thereof as compositions for treatment of cancer, and conjugates of imaging agent carriers and amino acids for the diagnosis of tumors and metastases.11-10-2011
20100056468Pyrimidine Derivatives As Anticancer Agents - The present invention includes methods of treating or preventing cancer by administering an effective amount of 6-substituted pyrimidine derivatives of the Formula I to a subject need thereof:03-04-2010
20110288045WET GRANULATION OF TENOFOVIR, EMTRICITABINE AND EFAVIRENZ - The present invention describes a method and composition for a pharmaceutical product based on Tenofovir disoproxil hemifumarate, Emtricitabine and Efavirenz. The composition can be prepared by a process comprising a wet granulation step to produce a stable dosage form suitable for the treatment of HIV in essential absence of known degradation products.11-24-2011
20100152129Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer - Synergistic combinations of gemcitabine with P276-00 or P1446A and their use in the treatment of cancer are disclosed. The invention further describes novel and unique gene signatures comprising gene markers used to monitor the drug response in a subject treated with the said combinations.06-17-2010
20090075931DEUTERIUM-ENRICHED CAPECITABINE - The present application describes deuterium-enriched capecitabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20120129799 STABLE COMPOSITION OF READY-TO-USE GEMCITABINE INJECTION - The present invention relates to non aqueous pharmaceutical preparations containing gemcitabine or its pharmaceutically, acceptable salts in the form of ready-to-use solutions wherein the concentration of Gemcitabine is in the range of about 16 mg/ml to about 200 mg/ml and a pH of about 3.5 to 10.0. Further, a method for the preparation of non-aqueous Gemcitabine solution of the present invention is also disclosed.05-24-2012
20090209482AZACYTIDINE ANALOGUES AND USES THEREOF - The present invention is directed toward compounds of Formula (I) as follows:08-20-2009
20100035835NUCLEOSIDE ARYL PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION - The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention.02-11-2010
20100267657ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER - A method treating cancer in a subject comprises administering to the subject a therapeutically effective amount of an antimetabolite agent that induces formation of AP sites in cancer cells of the subjects and an amount AP endonuclease inhibitor effective to potentiate the cytotoxicity of the antimetabolite agent to the cancer cells.10-21-2010
20100120709CYTIDINE DERIVATIVE-CONTAINING ANTITUMOR AGENT FOR CONTINUOUS INTRAVENOUS ADMINISTRATION - To provide a method for administering ECyd to a patient, which realizes a continuous therapy without expressing peripheral neurotoxicity caused by ECyd and which exhibits an excellent therapeutic effect with ensuring prolongation of the survival of the patient.05-13-2010
20110118205ANTI-TUMOR AGENT COMPRISING CYTIDINE DERIVATIVE AND CARBOPLATIN - Provision of a novel combined therapy with ECyd, which therapy exhibits remarkable antitumor effect and gives less adverse effects.05-19-2011
20090298791COMBINATIONS COMPRISING EPOTHILONES AND ANTIMETABOLITES - Disclosed is a combination which comprises (a) an antineoplastic antimetabolite and (b) an epothilone derivative of formula I12-03-2009
20120108534Dihydrothienopyrimidines for the treatment of inflammatory Diseases - The invention relates to new dihydrothienopyrimidine of formula 05-03-2012
20120108533NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS - This invention provides phosphate-modified nucleosides represented by the structural formula: wherein W is O or S, and wherein B, R05-03-2012
20090105186Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases - The invention relates to β-L-N4-hydroxycytosine nucleo-sides, pharmaceutical agents comprising same, and to the use of said β-L-N4-hydroxycytosine nucleosides and pharmaceutical agents in the prophylaxis or therapy of an infection caused by hepatitis B virus (HBV) or human immunodeficiency virus (HIV). The invention also relates to a method for the preparation of said β-L-nucleoside analogs.04-23-2009
20120295864METHOD FOR TREATING ACUTE MYELOID LEUKEMIA - The present invention relates to the use of BI 6727 or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) comprising the administration of a high dose of BI 6727 according to a specific dosage schedule, optionally in combination with cytarabine.11-22-2012
20090286754Method of Treating Cancer and Other Conditions or Disease States Using L-Cytosine Nucleoside Analogs - The present invention relates to the use of the compound according to formula (I) Where S is (A) or (B); X is H or F; R11-19-2009
20120289475Certain Compounds, Compositions and Methods - The present invention provides certain tetrahydrouridine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of making and using such compounds.11-15-2012
20110207692COMBINATIONS OF SAPACITABINE OR CNDAC WITH DNA METHYLTRANSFERASE INHIBITORS SUCH AS DECITABINE AND PROCAINE - A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject.08-25-2011
20100298256ANTIVIRAL COMPOUNDS - Lipid-modified phosphodiester nucleoside prodrugs are described herein. The prodrugs can be used to treat viral infections and cancer.11-25-2010
20100279975COMPOUNDS AND METHODS ASSOCIATED WITH DIFFERENTIAL METHYLATION OF HUMAN PAPILLOMA VIRUS GENOMES IN EPITHELIAL CELLS - The invention relates to compounds and methods useful in detection and therapy of HPV-associated diseases. The invention is based on the elucidation of a mechanism by which replication of HPVs occurs in naturally infected tissues and cells. Moreover it is based on the identification of distinct epigenetic changes of the viral genome in infected cells that allows promotion of the affected cells to precancerous and cancerous cells. The invention therefore provides methods of diagnosing neoplasias and their precursor lesions as well as methods of preventing the development of malignancies or inhibiting tumor growth.11-04-2010
20090005338Carbonyl-substituted titanocenes - A medicament containing a compound of the following formulas (Ia) and (Ib):01-01-2009
20080280850Methods and Compositions for Treating Flaviviruses, Pestiviruses and Hepacivirus - A method and composition for treating a host infected with flavivirus, pestivirus or hepacivirus comprising administering an effective flavivirus, pestivirus or hepacivirus treatment amount of a described base-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.11-13-2008
20120196828SENSITIZATION OF CANCER CELLS TO TREATMENT - The present application provides methods for the treatment of cancer, comprising administering substantially non-anticoagulant 2-O, 3-O desulfated heparin to patients suffering from cancer that is, or can become resistant to, cancer treatment, such as chemotherapy, targeted cancer therapy, or radiation therapy. The compositions can be administered to sensitize, or to reverse resistance to, cancer treatment, and can be administered alone or in combination with cancer treatment to subjects with solid tumors including, but not limited to, pancreatic, breast, renal, colorectal, gastric, or esophageal cancer, and subjects with hematologic malignancies, including but not limited to leukemia and lymphoma.08-02-2012
20090137521Certain Compounds, Compositions and Methods - The present invention provides certain tetrahydrouridine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of making and using such compounds.05-28-2009
20130217645Compounds and Compositions for the Treatment of Cancer - New uses for phenylketone carboxylate compounds and substituted aromatic compounds of Formula I, Formula I.1, Formula I.2, Formula IA, Formula IB, Formula IC and Formula II and their pharmaceutical acceptable salts for the treatment of cancer. The use of a combination of two of these compounds is described and the use of the combination of one of these compounds with an anticancer agent such as decarbazine, doxorubicin, daunorubicin, cyclophosphamide, busulfex, busulfan, vinblastine, vincristine, bleomycin, etoposide, topotecan, irinotecan, taxotere, taxol, 5-fluorouracil, methotrexate, gemcitabine, cisplatin, carboplatin and chlorambucil.08-22-2013
20090023679Compounds and methods for treatment of sickle cell disease or complications associated therewith - Compounds, compositions and methods are provided for treatment of sickle cell disease or a complication associated therewith, or graft versus host disease, in an individual. More specifically, the use of particular glycomimetics for the treatment is described.01-22-2009
20090203639Methylation Markers for Diagnoses and Treatment of Cancers - Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.08-13-2009
20090221522METHODS TO CORRECT GENE SET EXPRESSION PROFILES TO DRUG SENSITIVITY - The present invention comprises a treatment approach based on gene set-expression signatures that systematically connects a sample to a profile from a reference database to extrapolate the most effective therapeutic agent. Further disclosed are methods to optimize combination treatments.09-03-2009
20120196827METHYLATION MARKERS FOR EARLY DETECTION AND PROGNOSIS OF COLON CANCERS - Using a combination of analytic methods epigenetic silencing of markers in cancer have been determined. The cancers are generally those of the gastrointestinal tract including but not limited to esophageal, head and neck, gastric, pancreas, liver, and colon. The genes can be used for the early detection of cancer or can be used to identify adenomas that will likely progress to carcinomas. Therapeutic regimens based on the epigenetic silenced genes can be chosen and/or monitored. Kits for evaluating epigenetic silencing of these genes can be used for detection and monitoring.08-02-2012
20100056467COMBINATION OF IAP INHIBITORS AND FLT3 INHIBITORS - The present invention relates to methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the combination of a compound that inhibits the binding of the Smac protein to IAPs (“IAP inhibitor”) and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; and a commercial package comprising said combination. The present invention also relates to the use of IAP inhibitors in combination with one or more pharmaceutically active agents for the preparation of a medicament to treat hematological malignancies, including AML.03-04-2010
20100273731Medium-Chain Length Fatty Acids, Salts and Triglycerides in Combination with Gemcitabine for Treatment of Pancreatic Cancer - The present invention relates to the use of medium-chain length fatty acids of formula I, triglycerides of formula 2 (wherein n=6-10), salts thereof, or mixtures thereof, in combination with gemcitabine and optionally erlotinib in the treatment of pancreatic cancer in human patients. Exemplary medium-chain length fatty acid/triglyceride compounds include capric acid, sodium caprate, tricaprin, lauric acid, sodium laurate, and trilaurin.10-28-2010
20090048205COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE - The present invention concerns methods for treating cancer, such as pancreatic cancer, using combination therapies, including the combination of a synthetic triterpenoid, e.g., CDDO-Me, and gemcitabine.02-19-2009
20090048204NOVEL FORMS OF CDDO METHYL ESTER - A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.02-19-2009
20080214491Methods of Inhibiting the Interaction Between S100 and the Receptor for Advanced Glycation End-Products - A method of inhibiting an interaction between a S100 protein and the receptor for advanced glycation end-products is provided comprising administering to a subject a therapeutically effective amount of cromolyn, C5, or salt, hydrate, or solvate thereof. In some embodiments, the S100 protein is S100P. In some embodiments, the S100 protein is S100P. In addition, the present invention provides a method of treating a cancer comprising administering to a mammal a therapeutically effective amount of cromolyn, C5, or salt, hydrate, or solvate thereof. Additional methods are also provided.09-04-2008
20110059917VITAMIN D3 AND ANALOGS THEREOF FOR TREATING ALOPECIA - The invention provides methods and pharmaceutical compositions for preventing or treating alopecia, such as chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprises an effective amount of a vitamin D compound in a formulation that topically delivers the vitamin D compound to the epidermis layer but substantially avoids the dermis layer. In chemotherapy patients, the pharmaceutical compositions of the invention can be administered either before or concurrent with the chemotherapy medication.03-10-2011
20100152128Antiviral Agents - A compound of formula (I) and pharmaceutically acceptable salts thereof; compositions containing it and its use in medicine, particularly for the treatment or inhibition of HCV infections, and processes for making it are disclosed.06-17-2010
20100216737Inactivation of miR-34a by abberant CpG methylation in cancer - The present application refers to methods for cancer diagnosis and treatment, particularly in types of cancers associated with aberrant CpG methylation of the miR-34a promoter.08-26-2010
20100227833NOVEL NUCLEOSIDE ANALOGS FOR TREATMENT OF VIRAL INFECTIONS - This invention relates to novel compounds that have various medicinal applications, e.g. for the treatment and/or prevention of viral infections.09-09-2010
20090253648Tricyclic-Nucleoside Compounds for Treating Viral Infections - Disclosed are compounds represented by formulae I, II, and III, and the compositions and methods thereof for treating viral infections caused by a Flaviviridae family virus.10-08-2009
20120245118METHODS AND COMPOSITIONS FOR ALLEVIATING STUTTERING - Methods of treating stuttering include treating people with gamma-aminobutyric acid (GABA) receptor modulators, including cyclopyrrolones. A second active agent may be used with GABA receptor modulators. Active enantiomers, active metabolites, and pharmaceutically acceptable salts of gamma-aminobutyric acid receptor modulators, including cyclopyrrolones, are acceptable components of the compositions. The cyclopyrrolone class of modulators includes pagoclone, suriclone, zopiclone, 2-(7-chloro-2-naphthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-09-27-2012
20080306019Dopamine Receptor Agonists in the Treatment and Prevention of Hiv-Induced Dementia - Provided herein is a method of protecting a neuron from dysfunction induced by an HIV neurotoxin, comprising contacting the cell with a therapeutically effective dose of a dopamine D1 receptor agonist. Also provided is a method of treating or preventing HIV-1 associated dementia (HAD) in a subject in need of such treatment or prevention, comprising administering to the subject a therapeutically effective dose of a dopamine D1 receptor agonist and estrogenic compound.12-11-2008
20100222295Anti-Viral Pyrimidine Nucleoside Derivatives - A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH09-02-2010
20100311683CYTIDINE ANALOGS FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES - The present invention provides methods of treating a patient having a higher risk myelodysplastic syndrome, which comprises administering to a patient having a higher risk myelodysplastic syndrome a therapeutically effective amount of a cytidine analog. The cytidine analog includes 5-aza-2′-deoxy cytidine, 5-azacytidine, 5-aza-2′-deoxy- 2′,2′-difluorocytidine, 5-aza-2-40 -deoxy-2′-fluorocytidine, 2′-deoxy-2′,2′-difluorocytidine, cytosine 1-β-D-arabinofuranoside, 2(1H) pyrimidine riboside, 2′-cyclocytidine, arabinofuanosyl-5-azacytidine, dihydro-5-azacytidine, N12-09-2010
20090036399NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION - Disclosed are methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows:02-05-2009
20110130359METHODS FOR PREVENTING OR REDUCING NEUROTOXICITY ASSOCIATED WITH ADMINISTERING DPD INHIBITORS IN COMBINATION WITH 5-FU AND 5-FU PRODRUGS - Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme in both nervous and non-nervous tissues within the patient and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU generated from a prodrug is in substantial excess of DPD inhibitor in the patient.06-02-2011
20110021454MODIFIED 4`-NUCLEOSIDES AS ANTIVIRAL AGENTS - Compounds, methods and compositions for treating a host infected with human immunodeficiency virus and hepatitis B virus comprising administering an effective amount of a described 4′-C-substituted β-D- and β-L-nucleoside or a pharmaceutically acceptable salt or prodrug thereof, are provided.01-27-2011
201000564662'-Cyanopyrimidine Nucleoside Compound - The present invention provides a pyrimidine nucleoside compound represented by the following formula (1):03-04-2010
20110082100THERAPEUTIC SUBSTANCES THAT MODULATE GENOME METHYLATION - Compounds containing nucleic acid bases or their precursors modified by enrichment at specific sites with heavy stable isotopes of elements naturally present at those sites in minute amount are useful for the treatment of diseases characterized by altered gene expression and altered pattern of epigenomic control. These compounds, when used as nutrients or in other medicinal application methods, can alter the DNA methylation pattern in a simple way through the well-understood mechanism of kinetic isotope effect (KIE). This effect could also be useful for modifying methylation kinetics in stem cell technology, cloning and as disease therapeutics.04-07-2011
20110082101COMBINATIONS COMPRISING EPOTHILONES AND ANTI-METABOLITES - Disclosed is a combination which comprises (a) an antineoplastic antimetabolite and (b) an epothilone derivative of formula I04-07-2011
20110071100SULFOBETAINES FOR CANCER, OBESITY, MACULAR DEGENERATION, NEURODEGENERATIVE DISEASES - The subject of the invention provides a pharmaceutical composition comprising a sulfobetaine, a sulfobetaine for therapy, uses thereof and methods of treating cancer obesity, age related macular degeneration or neurodegenerative diseases comprising administering a composition comprising a sulfobetaine.03-24-2011
20100004193COMBINATION THERAPY - A method of treating a subject affected by neoplastic diseases includes the administration to the subject of an aminoglycoside antibiotic in combination with a nucleoside analogue.01-07-2010
20120202765EFFECTIVE TREATMENT OF ESOPHOGEAL ADENOCARCINOMA USING TRICIRIBINE AND RELATED COMPOUNDS - The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat esophogeal adenocarcinoma by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.08-09-2012
20120202766N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS - The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2′,3′-dideoxy-5-fluorocytidine or N.sup.4-acyl-2′,3′-didehyd-ro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.08-09-2012
20090118222NOVEL PYRIMIDINE NUCLEOSIDE COMPOUND OR ITS SALT - A novel pyrimidine nucleoside compound represented by the following formula (1):05-07-2009
20100273730SELF-EMULSIFYING PHARMACEUTICAL COMPOSITIONS OF HYDROPHILIC DRUGS AND PREPARATION THEREOF - The present invention provides an oral self micro-emulsifying pharmaceutical composition of a hydrophilic drug or a pharmaceutically acceptable salt thereof which, in addition to the hydrophilic drug, one or more solvents for solving the hydrophilic drug to form a drug-solvent solution and a surfactant system, further comprises one or more hydrophilic carrier which are compatible with said drug-solvent solution and the surfactant system. The oral self micro-emulsifying pharmaceutical composition of the invention exhibits comparative bioavailability to that of the hydrophilic drug through injection and is stable during storage. A method for preparing the oral self micro-emulsifying pharmaceutical composition is also provided.10-28-2010
20110028423AGENT THAT MODULATES PHYSIOLOGICAL CONDITION OF PESTS, INVOLVED IN INSECT CHOLINE ACETYLTRANSFERASE ACTIVITY - The present invention provides an agent that modulates physiological condition of pests, wherein the agent has an ability to modulate the activity of an insect choline acetyltransferase; a method for assaying pesticidal activity of a test substance, which comprises measuring the activity of a choline acetyltransferase in a reaction system in which the choline acetyltransferase contacts with a test substance, and the like.02-03-2011
20110263525DRUG COMPOSITION CYTOTOXIC FOR PANCREATIC CANCER CELLS - The invention describes a cytotoxic composition containing a drug combination targeting two or more functional elements in pancreatic cancer cells, the functional elements comprising EGFR or Src and Stat3 or Jaks. Preferred drugs in the drug combination are selected from ZD and S3I-201, Das and S3I-201, ZD and AG490, Das and AG490, and combinations thereof. In a preferred embodiment of the invention, the drug combination further includes a nucleoside analog inhibitory for DNA replication, for example, Gemcitabine. Disclosed is also a method of cytotoxically affecting pancreatic cancer cells using the described drug combination. A method of making the cytotoxic composition is additionally described.10-27-2011
20110136756COMBINATION ANTITUMOR THERAPY - The present disclosure relates to methods of treating cancers that are responsive to antimetabolite or antimitotic anti-cancer agents. The methods involve the use of at least one anti-cancer agent selected from antimetabolite anti-cancer agents, antimitotic anti-cancer agents, and combinations thereof, and a superoxide dismutase mimetic to potentiate the therapeutic effect of the anti cancer agent(s).06-09-2011
20120302520GEMCITABINE COMBINATION THERAPY - The present invention provides compositions and methods for the treatment of cell proliferative disorders using at least one DAC inhibitor and gemcitabine.11-29-2012
20100120708Combination therapy comprising ZD6474 and gemcitabine for anti-cancer therapy - The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of ZD6474 in combination with gemcitabine; to a pharmaceutical composition comprising ZD6474 and gemcitabine; to a combination product comprising ZD6474 and gemcitabine for use in a method of treatment of a human or animal body by therapy; to a kit comprising ZD6474 and gemcitabine; to the use of ZD6474 and gemcitabine in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.05-13-2010
20090176731COMBINATION THERAPY OF CANCER WITH AZD2171 AND GEMCITABINE - The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of AZD2171 in combination with gemcitabine; to a pharmaceutical composition comprising AZD2171 and gemcitabine; to a combination product comprising AZD2171 and gemcitabine for use in a method of treatment of a human or animal body by therapy; to a kit comprising AZD2171 and gemcitabine; to the use of AZD2171 and gemcitabine in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.07-09-2009
20090176730N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS - The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2′,3′-dideoxy-5-fluorocytidine or N.sup.4-acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.07-09-2009
20110263524SNS-595 AND METHODS OF USING THE SAME - The present invention relates to SNS-595 and methods of treating cancer using the same.10-27-2011
20100099644HPMA - DOCETAXEL OR GEMCITABINE CONJUGATES AND USES THEREFORE - Disclosed are water-soluble compositions of gemcitabine and docetaxel formed by conjugating the gemcitabine or docetaxel to a water-soluble polymer such as N-2-hydroxypropyl methacrylamide (HPMA). Also disclosed are methods of using the compositions of the invention for the treatment of cancer.04-22-2010
20100022468NUCLEOSIDE CYCLIC PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION - The present invention provides nucleoside cyclic phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as pre-cursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside cyclic phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside cyclic phosphoramidates of the present invention.01-28-2010
20090149417Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors - The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.06-11-2009
20080280851Oral Dosage Forms of Gemcitabine Derivatives - The present invention relates to oral dosage forms of certain long chain saturated and monounsaturated fatty acid derivatives of 2′,2′-difluorodeoxycytidine (Gemcitabine). In particular, the present invention relates to the use of the said gemcitabine derivatives or a pharmaceutical acceptable salt thereof for preparing an oral dosage form ameliorating compliance in treatment of cancer.11-13-2008
20100062996DIOXOLANE DERIVATES FOR THE TREATMENT OF CANCER - This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula (I)” herein. Compounds of formula (I) can be used in the treatment of a cancerous disease. Treatment of both solid tumours and haematological cancers such as leukaemias, lymphomas and multiple myelomas are included.03-11-2010
20090209483TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION - The present invention provides methods for treating infections, in a host, by viruses belonging to the Flaviviridae family, such as HCV, comprising administering an Ara-C homologue to the host.08-20-2009
20090203640CRYSTALLINE FORMS OF GEMCITABINE AMIDE PRODRUG, COMPOSITIONS AND USE THEREOF - The present invention relates to novel crystal forms of an amide prodrug of gemcitabine, compositions thereof and methods for using.08-13-2009
20100184716PHARMACEUTICAL COMPOSITIONS WITH SUPERIOR PRODUCT PERFORMANCE AND PATIENT COMPLIANCE - The present invention provides novel formulations of isobutyric acid (2R,3R,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-4-fluoro-2-isobutyryloxymethyl-4-methyl-tetrahydro-furan-3-yl ester) and hydroxypropylcellulose that provide high bulk density, low particle size better suited for improved compression and flow, good compression, and fast dissolution profiles.07-22-2010
20110306572COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2] - Described herein are compositions and methods for using these compositions in the treatment of cancer, tumors, and tumor-related disorders in a subject.12-15-2011
20090118223Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives - Novel 2′-C-methyl nucleoside 5′-monophosphate and 4′-C-methyl nucleoside 5′-monophosphate derivatives, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described.05-07-2009
20100016253METHODS AND COMPOSITIONS RELATED TO HEIGHTENED APOBEC-1 RELATED PROTEIN (ARP) EXPRESSION - Disclosed are methods and compositions related to determining the status and mechanisms underlying long-term nonprogression of viral infections.01-21-2010
20120040925ARYL UREA COMPOUNDS IN COMBINATION WITH OTHER CYTOSTATIC OR CYTOTOXIC AGENTS FOR TREATING HUMAN CANCERS - This invention relates to aryl urea compounds in combination with cytotoxic or cytostatic agents for use in treating raf kinase mediated diseases such as cancer.02-16-2012
20120309706COMBINED TREATMENT OF PANCREATIC CANCER WITH GEMCITABINE AND MASITINIB - The present invention relates to the combined treatment of pancreatic cancers, especially in patients with metastasis and in patients whose cancer is developing resistance to first line treatment with gemcitabine, comprising administration of masitinib and gemcitabine, both in appropriate dosage regimens allowing resensitisation of cancer cells to gemcitabine.12-06-2012
20100197628METHODS OF TREATING PSYCHIATRIC, SUBSTANCE ABUSE, AND OTHER DISORDERS USING COMBINATIONS CONTAINING OMEGA-3 FATTY ACIDS - The invention provides methods for treating or preventing psychiatric disorders, substance abuse disorders, and other conditions, e.g., cardiovascular disease and cancer, involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, adenosine-elevating compound, omega-3 fatty acids, or combinations thereof to a mammal. The invention further provides methods of enhancing neurodevelopment and delaying premature pregnancy by administration of an effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, adenosine-elevating compound, omega-3 fatty acids, or combinations thereof to a mammal.08-05-2010
20120252753THERAPEUTIC TARGET FOR PANCREATIC CANCER CELLS - This invention provides a therapeutic target for pancreatic cancer. The invention further provides methods of screening of new therapeutic agents using the target. The invention also provides a pharmaceutical composition comprising fasudil or derivatives thereof for pancreatic cancer treatment, and a kit comprising such a pharmaceutical composition.10-04-2012
20100279976USE OF ARTEMISININ AND ITS DERIVATIVES IN CANCER THERAPY - A method for treating cancer in a mammal includes administering to the mammal in need thereof a therapeutically effective amount of artemisinin (ART) or its derivative, such as dihydroartemisinin (DHA), artemether (ARM), or artesunate (ARS) alone or in combination with a chemotherapeutic agent, such as gemcitabine and carboplatin. A method for inhibiting tumor cell proliferation includes contacting a tumor cell with ART or its derivative, such as DHA, ARM, and ARS, in an amount effective to inhibit tumor cell proliferation or in combination with a chemotherapeutic agent, such as gemcitabine and carboplatin.11-04-2010
20120108532PHARMACEUTICAL COMPOSITION FOR NEUROPROTECTIVE TREATMENT IN PATIENTS WITH ICTUS COMPRISING CITICOLINE AND URIC ACID - A pharmaceutical composition comprised of uric acid and citicoline is for the neuroprotective treatment of patients with ictus.05-03-2012
20110166095CANCER PLATINUM RESISTANCE DETECTION AND SENSITIZATION METHOD - The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.07-07-2011
20120015899MODIFIED PLANT VIRUS PARTICLES AND USES THEREFOR - Aspects of the invention provide modified virus-like particles that are designed for therapeutic applications. In particular, aspects of the invention provide CCMV coat proteins that are modified to generate virus-like particles, including mosaic virus-like particles, that can package and/or deliver one or more diagnostic and/or therapeutic agents. The invention also provides methods for treating subjects with one or more modified virus-like particles.01-19-2012
20100137239GEMCITABINE COMBINATION THERAPY - The present invention provides compositions and methods for the treatment of cell proliferative disorders using at least one DAC inhibitor and gemcitabine.06-03-2010
20120157404ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.06-21-2012
20110092452COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PANCREATIC CANCER - The present invention provides compositions and methods for treating and diagnosing the presence of solid tumor stem cells in a patient (e.g., based on the presence of c-Met). In certain embodiments, the presence or absence of solid tumor stem cells (e.g., pancreatic solid tumor stem cells) can be determined through the use of a single cells surface marker (e.g., c-Met). The present invention also provides methods for screening candidate compounds (e.g., c-Met antagonists) for the ability to inhibit the tumorigenisis of pancreatic solid tumor stem cells.04-21-2011
20120316128CITICOLINE FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION - The present invention refers to citicoline and to compositions containing it for topic use in treating glaucoma and/or ocular hypertension.12-13-2012
20120316127METHOD OF MANUFACTURING COATING AGENT FOR DRUG RELEASING STENT AND COATING AGENT FOR DRUG RELEASING STENT MANUFACTURED THEREBY - This invention relates to a method of manufacturing a coating agent for a drug releasing stent and to a coating agent for a drug releasing stent manufactured thereby. This method includes (1) dissolving polyurethane in tetrahydrofuran, (2) dissolving pluronic F-127 in tetrahydrofuran, (3) dissolving a gemcitabine compound in ethanol, (4) mixing these three solutions obtained in (1) to (3) thus preparing a solution mixture, (5) applying the solution mixture obtained in (4) on a stent coated with a Teflon film, (6) drying the stent of (5) for a predetermined period of time and then immersing the stent in a polyurethane solution in tetrahydrofuran, and (7) removing the stent immersed in (6) from the polyurethane solution and then drying the stent, so that the rate of release of an anti-cancer drug applied on the stent can be continuously and maximally improved thereby maximizing anti-cancer efficacy.12-13-2012
20120135953Bis-Benzimidazole Derivatives As Hepatitis C Virus Inhibitors - Inhibitors of HCV replication of formula I05-31-2012
20120135952BUTYRIC ACID SALT OF N,N-DIMETHYL IMIDOCARBON IMIDIC DIAMIDE, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS CONTAINING SAME - The present invention provides metformin butyric acid salt, a method of preparing the same, and pharmaceutical compositions and combinations containing the same. The metformin butyric acid salt according to the present invention has an excellent pharmacological effect as compared with metformin hydrochloride and is capable of achieving a therapeutic purpose by administering an amount less than metformin hydrochloride. Furthermore, the metformin butyric acid salt has excellent physicochemical properties, such as solubility, stability, hygroscopicity and adsorption preventing property, in processibility of formulations and thereby is capable of being usefully utilized as a pharmaceutically acceptable salt of the metformin.05-31-2012
20100190738Use of Aalkylphophocholines in Combination with Antitumor Medication for the Treatment of Benign and Melignant Oncoses in Humans and Mammals - The invention relates to the use of alkylphosphocholines in combination with antimetabolite antitumor substances for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or more antimetabolite antitumor substances. Preferred alkylphosphocholines are described by the Formula II.07-29-2010
20100048503COMPOSITION FOR TREATMENT OF PANCREATIC CANCER - Disclosed are a pharmaceutical composition having excellent antitumor activity, and a method for treating a cancer. Specifically, excellent antitumor activity is achieved when 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or an analogous compound thereof, a pharmacologically acceptable salt thereof or a solvate thereof is used in combination with gemcitabine or erlotinib, a pharmacologically acceptable salt thereof or a solvate of any of them.02-25-2010
20100273732COMBINATION METHODS OF TREATING CANCER - The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.10-28-2010
20100009930TREATMENT OF UTERINE CANCER AND OVARIAN CANCER WITH A PARP INHIBITOR ALONE OR IN CONBINATION WITH ANTI-TUMOR AGENTS - In one aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.01-14-2010
20100009928COMPOSITIONS INCLUDING TRICIRIBINE AND TAXANES AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine and related compounds and taxanes and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.01-14-2010
20100292181COMPOSITIONS AND METHODS FOR DETECTING AND TREATING HIV INFECTIONS - HIV infection can be detected by measuring phosphorylation levels of the actin-depolymerizing factor (AFD)/cofilin family, and infection can be treated and/or prevented by modulating the HIV co-receptor signaling pathway.11-18-2010
20120190639TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS - The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.07-26-2012
20120264710Systems and Methods for Detecting hENT1 Expression in Hematological Disorders - This invention relates generally to methods, assays and systems for detecting hENT1 expression levels in hematological disorders, to methods, assays and systems for detecting hENT1 expression levels in hematological disorders using flow cytometry, and to methods, assays and systems for detecting hENT1 expression levels in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) using flow cytometry. The invention also relates to diagnostic and therapeutic uses for the detection of hENT1 expression levels in a subject.10-18-2012
20100168051Altered Mitochondrial Activity in Diseases Resulting From Oxidative Stress - The present invention relates to the identification of a subject having or at risk of developing a disease resulting from oxidative stress in the body. The present invention also relates to the identification of a diabetic subject having or at risk of developing microvascular disease, kidney disease, and/or cardiovascular disease.07-01-2010
20120322755CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION - This invention provides a cytosine analogue, a method of preparation of a cytosine analogue, a DNA rhethyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal DNA methylation. More precisely, the invention relates to various derivatives of cytosine, as well as methods of preparation of mono- and multi-1,4,5 and 6-substituted cytosines. In general, the solution relates to providing effective modulators of DNA methylation which could be used in prevention and treatment of diseases associated with DNA methylation level disorders.12-20-2012
20120270831METHOD FOR TREATING HEMATOPOIETIC NEOPLASMS - This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.10-25-2012
20100234316Nucleoside Aryl Phosphoramidates for the Treatment of RNA-Dependent RNA Viral Infection - The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention.09-16-2010
20120101057COMBINED THERAPY OF COLORECTAL CARCINOMA - The invention relates to a combined therapy, wherein addition of a vitamin D analogue to the standard treatment regimen based on cytostatics, 5-fluorouracil and/or its precursors, generates potential possibility of achieving beneficial therapeutic effect in the first-line chemotherapy or adjuvant therapy of colorectal carcinoma. Vitamin D analogues are selected from a group consisting of tacalcitol, calcipotriol and 5,6-trans-isomer of calcipotriol.04-26-2012
20100173864COMPOSITIONS INCLUDING TRICIRIBINE AND ONE OR MORE PLATINUM COMPOUNDS AND METHODS OF USE THEREOF - This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.07-08-2010
20130023491BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE - In the invention provides for a method of stimulating or increasing β-cell replication or growth, by contacting a β-cell with an inhibitor of adenosine kinase (ADK), an inhibitor of S-Adenosylhomocysteine hydrolase (SAHH) or an activator of AMP activated protein kinase (AMPK).01-24-2013
20080234223N4 MODIFICATIONS OF PYRIMIDINE ANALOGS AND USES THEREOF - The present invention relates to N4 carboxylester or ester derivatives of pyrimidine analogs with increased stability, solubility, and bioavailability. Also disclosed are methods of using these compounds for targeted drug delivery and combination therapy.09-25-2008
20080221061Lung-Targeted Drugs - Methods and compositions are provided for treating lung diseases, including but not limited to infections and small cell and non-small cell lung cancer, by conjugating a drug of interest to glycerol ethers or glycerol phosphate ethers.09-11-2008
20130096079Anti-Viral Pyrimidine Nucleoside Derivatives - A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH04-18-2013
20130102559METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OX- O-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF ANTECEDENT HEMATOLOGIC DISORDERS - Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.04-25-2013
20130116209METHOD FOR SELECTION OF CHEMOTHERAPEUTIC AGENTS FOR ADENOCARCINOMA CANCER - The subject invention relates to determining the presence and level of hENT1 expression in tumor tissue that is appropriate for gemcitabine therapy, and more importantly, the level of hENT1 expression that signifies that treatment with a gemcitabine derivative is a more appropriate strategy.05-09-2013
20130131008LIPOPHILIC MONOPHOSPHORYLATED DERIVATIVES AND NANOPARTICLES - There are provided, inter alia, lipophilic monophosphorylated derivatives of gemcitabine. There are further provided nanoparticles compositions incorporating lipophilic monophosphorylated derivatives of gemcitabine, pharmaceutical compositions thereof, and a method of treating cancer or a viral infection in a subject in need thereof, which method includes administration of a pharmaceutical composition disclosed herein.05-23-2013
20130143834Cancer Treatment Method - The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional anti-neoplastic compound.06-06-2013
20100279974Nucleosides With Non-Natural Bases as Anti-Viral Agents - A method and composition for treating a host infected with flavivirus, pestivirus or hepacivirus comprising administering an effective flavivirus, pestivirus or hepacivirus treatment amount of a described base-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.11-04-2010
20110218170USE OF 2'-DEOXY-4'-THIOCYTIDINE AND ITS ANALOGUES AS DNA HYPOMETHYLATING ANTICANCER AGENTS - Compounds represented by the formulae:09-08-2011
201102755893,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF - The invention is directed to 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions containing them, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds and prodrugs.11-10-2011
20100311684NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS - Nucleosides and nucleotides containing a tricyclic base portion thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer respectively.12-09-2010
20100317612METHOD OF OBTAINING OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES, AN ANTI-AGING COMPOSITION AND USE OF 4-N-FURFURYLCYTOSINE AND/OR ITS DERIVATIVES IN THE MANUFACTURE OF ANTI-AGING COMPOSITION - The subjects of the present invention are the method of preparation of 4-furfurylcytosine and/or its derivatives, its use in the manufacture of anti-aging compositions and an anti-aging composition. As 4-furfurylcytosine and/or its derivatives possesses a series of biological properties it might be use as a composition having excellent anti-aging effect to prevent the sagging of skin and loss of luster and to improve sufficiently its aesthetic appearance without significantly change the growth rate and the total growth ability of the skin. Optimal methods of manufacturing this compound, while at the same time obtaining the highest possible process efficiency, with particular emphasis on its utility in the pharmaceutical and cosmetic industries are presented.12-16-2010
20130157972COMPOSITIONS INCLUDING TRICIRIBINE AND BORTEZOMIB AND DERIVATIVES THEREOF AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.06-20-2013
20110294754NOVEL PHARMACEUTICAL COMPOUNDS - Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders.12-01-2011
20110312909THERAPEUTIC COMBINATION COMPRISING A CDKS INHIBITOR AND AN ANTINEOPLASTIC AGENT - The present invention provides a therapeutic combination comprising (a) a compound of formula (I) as set forth in the specification and (b) one or more antineoplastic agents selected from the group consisting of alkylating or alkylating-like agents, antimetabolite agents and topoisomerase I inhibitors, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof.12-22-2011
20130196941PARENTERAL FORMULATIONS OF ELACYTARABINE DERIVATIVES - The present invention relates to parenteral formulations for certain long chain saturated and monounsaturated fatty acid derivatives of 1-β-D-arabinofuranosylcytosine (cytarabine). In particular, the present invention relates to a parenteral pharmaceutical composition and a method of the preparation thereof, in order to accommodate therapeutically effective doses of the said derivatives ameliorating compliance in treatment of cancer.08-01-2013
20120071435PHARMACEUTICAL COMBINATIONS COMPRISING FOR THE TREATMENT OF SPECIFIC CANCERS - The present invention relates to the field of oncology and provides compositions and methods for treating specific cancers, including non small cell lung cancer, breast cancer, thyroid cancer, pancreatic cancer, colon cancer, melanoma, hepatoma and adenocarcinoma. Particularly, compositions and methods involving administration, either simultaneously or sequentially, of pharmaceutical combinations comprising (S)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide with other compounds, to patients suffering from cancer are described.03-22-2012
20120094949HISTONE MODIFICATION PATTERNS FOR CLINICAL DIAGNOSIS AND PROGNOSIS OF CANCER - The present invention provides methods of diagnosing and providing a prognosis and therapy for cancer including, but not limited to, pancreatic cancer and responsiveness to thymidylate synthase inhibitor (e.g., 5-FU) therapy, by identifying cancers with altered histone modification patterns selected from the group consisting of H3K4me2, H3K9me2, or H3K18ac.04-19-2012

Patent applications in class Pyrimidines (including hydrogenated) (e.g., cytosine, etc.)

Patent applications in all subclasses Pyrimidines (including hydrogenated) (e.g., cytosine, etc.)